About Torsin-1A-interacting protein 2
Torsin-1A-interacting protein 2 (TOR1AIP2) is a protein
from Homo sapiens identified by UniProt accession
Q8NFQ8, 470 residues long.
MolForge cross-references it against 0 known binders and
19 disease associations.
Target properties
| Protein name | Torsin-1A-interacting protein 2 |
| UniProt accession | Q8NFQ8 |
| Gene | TOR1AIP2 |
| Organism | Homo sapiens |
| Length | 470 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (19)
Diseases linked to this target (Open Targets).
- cystatin C measurement · score 0.19
- Abnormality of refraction · score 0.08
- mean corpuscular volume · score 0.05
- mean reticulocyte volume · score 0.04
- mean corpuscular hemoglobin · score 0.03
- prostate carcinoma · score 0.03
- mean corpuscular hemoglobin concentration · score 0.03
- smoking behavior · score 0.02
- smoking initiation · score 0.02
- Hepatic steatosis · score 0.01
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-Q8NFQ8-F1 | alphafold | PREDICTED | 69.19 | — |
Amino-acid sequence (470 residues)
MADSGLREPQ EDSQKDLEND PSVNSQAQET TIIASNAEEA EILHSACGLS KDHQEVETEG PESADTGDKS ESPDEANVGK HPKDKTEDEN KQSFLDGGKG HHLPSENLGK EPLDPDPSHS PSDKVGRADA HLGSSSVALP KEASDGTGAS QEPPTTDSQE AQSPGHSSAG QEGEDTLRRR LLAPEAGSHP QQTQKLEEIK ENAQDTMRQI NKKGFWSYGP VILVVLVVAV VASSVNSYYS SPAQQVPKNP ALEAFLAQFS QLEDKFPGQS SFLWQRGRKF LQKHLNASNP TEPATIIFTA AREGRETLKC LSHHVADAYT SSQKVSPIQI DGAGRTWQDS DTVKLLVDLE LSYGFENGQK AAVVHHFESF PAGSTLIFYK YCDHENAAFK DVALVLTVLL EEETLEASVG PRETEEKVRD LLWAKFTNSD TPTSFNHMDS DKLSGLWSRI SHLVLPVQPV SSIEEQGCLF
Explore Torsin-1A-interacting protein 2 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets